March 3, 2020
Otsuka Pharmaceutical has inked a copromotion agreement in Japan for Novartis Pharma’s approval-pending heart failure treatment LCZ696 (sacubitril valsartan sodium hydrate), which has already grown into a blockbuster overseas under the brand name of Entresto, the two partners said on...read more